414 related articles for article (PubMed ID: 21097776)
41. Xeroderma pigmentosum clinical practice guidelines.
Moriwaki S; Kanda F; Hayashi M; Yamashita D; Sakai Y; Nishigori C;
J Dermatol; 2017 Oct; 44(10):1087-1096. PubMed ID: 28771907
[TBL] [Abstract][Full Text] [Related]
42. Thyroid nodules in xeroderma pigmentosum patients: a feature of premature aging.
Kouatcheu SD; Marko J; Tamura D; Khan SG; Lee CR; DiGiovanna JJ; Kraemer KH
J Endocrinol Invest; 2021 Jul; 44(7):1475-1482. PubMed ID: 33155181
[TBL] [Abstract][Full Text] [Related]
43. Establishment and characterization of a melanoma cell line from a xeroderma pigmentosum patient: activation of N-ras at a potential pyrimidine dimer site.
Keijzer W; Mulder MP; Langeveld JC; Smit EM; Bos JL; Bootsma D; Hoeijmakers JH
Cancer Res; 1989 Mar; 49(5):1229-35. PubMed ID: 2645048
[TBL] [Abstract][Full Text] [Related]
44. Characteristics of Xeroderma Pigmentosum in Japan: Lessons From Two Clinical Surveys and Measures for Patient Care.
Nishigori C; Nakano E; Masaki T; Ono R; Takeuchi S; Tsujimoto M; Ueda T
Photochem Photobiol; 2019 Jan; 95(1):140-153. PubMed ID: 30565713
[TBL] [Abstract][Full Text] [Related]
45. High mutation frequency in ras genes of skin tumors isolated from DNA repair deficient xeroderma pigmentosum patients.
Daya-Grosjean L; Robert C; Drougard C; Suarez H; Sarasin A
Cancer Res; 1993 Apr; 53(7):1625-9. PubMed ID: 8453633
[TBL] [Abstract][Full Text] [Related]
46. [Xeroderma pigmentosum. A study in 40 Algerian patients].
Bouadjar B; Aït-Belkacem F; Daya-Grosjean L; Sarasin A; Larbaoui SL; Ferhat R; Cherid MC; Bendissari A; Chouiter A; Bouzid K; Henni T; Hafiz A; Allouache A; Ysmail-Dahlouk M
Ann Dermatol Venereol; 1996; 123(5):303-6. PubMed ID: 8761081
[TBL] [Abstract][Full Text] [Related]
47. DNA repair characteristics and skin cancers of xeroderma pigmentosum patients in Japan.
Takebe H; Miki Y; Kozuka T; Furuyama JI; Tanaka K
Cancer Res; 1977 Feb; 37(2):490-5. PubMed ID: 832273
[TBL] [Abstract][Full Text] [Related]
48. Brazilian XP-E siblings carrying a novel DDB2 variant developed early-onset melanoma: a case report.
de Souza Timoteo AR; Pinheiro de Almeida IC; Yurchenko AA; de Miranda Henriques SR; de Souza Segundo P; Rajabi F; Nikolaev S; Petta TB
BMC Med Genomics; 2023 Aug; 16(1):186. PubMed ID: 37573316
[TBL] [Abstract][Full Text] [Related]
49. The cyclopurine deoxynucleosides: DNA repair, biological effects, mechanistic insights, and unanswered questions.
Brooks PJ
Free Radic Biol Med; 2017 Jun; 107():90-100. PubMed ID: 28011151
[TBL] [Abstract][Full Text] [Related]
50. Orbital amelanotic melanoma in xeroderma pigmentosum: a rare association.
Rizvi SA; Amitava AK; Mehdi G; Sharma R; Alam MS
Indian J Ophthalmol; 2008; 56(5):421-3. PubMed ID: 18711275
[TBL] [Abstract][Full Text] [Related]
51. Clinically asymptomatic xeroderma pigmentosum neurological disease in an adult: evidence for a neurodegeneration in later life caused by defective DNA repair.
Robbins JH; Brumback RA; Moshell AN
Eur Neurol; 1993; 33(3):188-90. PubMed ID: 8467834
[TBL] [Abstract][Full Text] [Related]
52. Xeroderma pigmentosum group C in a French Caucasian patient with multiple melanoma and unusual long-term survival.
Jacobelli S; Soufir N; Lacapere JJ; Regnier S; Bourillon A; Grandchamp B; Hétet G; Pham D; Palangie A; Avril MF; Dupin N; Sarasin A; Gorin I
Br J Dermatol; 2008 Sep; 159(4):968-73. PubMed ID: 18717677
[TBL] [Abstract][Full Text] [Related]
53. Xeroderma pigmentosum: heterogeneous syndrome and model for UV carcinogenesis.
Jung EG
Bull Cancer; 1978; 65(3):315-21. PubMed ID: 719183
[TBL] [Abstract][Full Text] [Related]
54. Reduced levels of UV-induced unscheduled DNA synthesis in epidermal keratinocytes of patients with xeroderma pigmentosum and correlation with development of skin neoplasms.
Kondo S; Satoh Y; Kuroki T
Cancer Res; 1989 Apr; 49(8):1927-30. PubMed ID: 2467739
[TBL] [Abstract][Full Text] [Related]
55. Understanding Xeroderma Pigmentosum Complementation Groups Using Gene Expression Profiling after UV-Light Exposure.
Bowden NA; Beveridge NJ; Ashton KA; Baines KJ; Scott RJ
Int J Mol Sci; 2015 Jul; 16(7):15985-96. PubMed ID: 26184184
[TBL] [Abstract][Full Text] [Related]
56. The risk of malignant melanoma, internal malignancy and mortality in xeroderma pigmentosum patients.
English JS; Swerdlow AJ
Br J Dermatol; 1987 Oct; 117(4):457-61. PubMed ID: 3676093
[TBL] [Abstract][Full Text] [Related]
57. Genetic correction of DNA repair-deficient/cancer-prone xeroderma pigmentosum group C keratinocytes.
Arnaudeau-Bégard C; Brellier F; Chevallier-Lagente O; Hoeijmakers J; Bernerd F; Sarasin A; Magnaldo T
Hum Gene Ther; 2003 Jul; 14(10):983-96. PubMed ID: 12869216
[TBL] [Abstract][Full Text] [Related]
58. Xeroderma pigmentosum at a tertiary care center in Saudi Arabia.
Alwatban L; Binamer Y
Ann Saudi Med; 2017; 37(3):240-244. PubMed ID: 28578364
[TBL] [Abstract][Full Text] [Related]
59. Xeroderma pigmentosum genes and melanoma risk.
Paszkowska-Szczur K; Scott RJ; Serrano-Fernandez P; Mirecka A; Gapska P; Górski B; Cybulski C; Maleszka R; Sulikowski M; Nagay L; Lubinski J; Dębniak T
Int J Cancer; 2013 Sep; 133(5):1094-100. PubMed ID: 23436679
[TBL] [Abstract][Full Text] [Related]
60. Analysis of point mutations in an ultraviolet-irradiated shuttle vector plasmid propagated in cells from Japanese xeroderma pigmentosum patients in complementation groups A and F.
Yagi T; Tatsumi-Miyajima J; Sato M; Kraemer KH; Takebe H
Cancer Res; 1991 Jun; 51(12):3177-82. PubMed ID: 2039995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
